知镜 Cognispect · 医学文献与研究工作台

β-Glucan-based oral nano/micro delivery systems: harnessing dual immunomodulatory and microbiota-modulating properties for targeted therapy of cancer and inflammatory bowel disease.

Fu Y, Cao C, Jiao Y, Cao Y, Hao H, Cui X, Gao D, Gao Y, Zhang Q, Liu Y.
Nanoscale · 2026-11-05 · PMID 42861695

文献摘要

The efficacy of oral drug delivery is often constrained by gastrointestinal physiological barriers and the hepatic first-pass effect, while conventional oral formulations lack the capability of targeted release at intestinal lesions, creating an urgent need for innovative functional delivery carriers. β-Glucan, an abundant natural polysaccharide, holds great potential for constructing intelligent oral nano/micro delivery systems, owing to its resistance to human digestive enzymes and its inherent dual immunomodulatory and microbiota-regulating properties. This carrier not only serves as an ideal protective vehicle but also bypasses the first-pass effect via M-cell-mediated lymphatic targeting and achieves site-specific drug release at pathological sites through its susceptibility to colonic microbiota enzymatic degradation. This review emphasizes the structural diversity, structure-activity relationships, and combined immunomodulatory/microbiota-modulating functions of β-glucan. It further explains how M-cell targeting and microbiota responsiveness are integrated to overcome gastrointestinal barriers for precise intestinal and systemic delivery. Recent advances in β-glucan-based nano/micro delivery systems for the treatment of cancer and inflammatory bowel disease are also highlighted. Finally, current challenges and future directions for β-glucan-based oral nano/micro delivery systems are outlined. In summary, the unique properties of β-glucan offer exciting new opportunities for targeted oral drug delivery.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。